Price
No data yet.
Social Signal Score
Analyst Ratings
8 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Oren Gilad
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 8
- Beta
- 1.63
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- -9.84
Financials
Revenue
$0.00-100.0%Net Income
$-3.59MEBITDA
$-3.59MFree Cash Flow
$-3.29MEPS (diluted)
$-0.07Shares Outstanding (diluted)
53.48M+7499.4%Operating Expenses
$4.03MCash & Debt
$41.23MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-12.60M | $-1.93 |
| 2024 | $1.50M | $-12.96M | $-2.35 |
| 2023 | $583.2K | $-14.29M | $-3.95 |
| 2022 | $0.00 | $-112.66M | $-1359.79 |
| 2021 | $0.00 | $-36.54M | $-34.88 |
| 2020 | $0.00 | $-53.92M | $-50.61 |
| 2019 | $0.00 | $-28.06M | $-26.28 |
| 2018 | $0.00 | $-15.53M | $-22.06 |
| 2017 | $0.00 | $-15.19M | $-21.58 |
Valuation
APREhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100+0.00%Social Signal Score
Mentions (2)
- Newsglobenewswire.com·1d ago·Neutral
Aprea Therapeutics to Present at October Conferences Company to participate in 2026 Maxim Growth Summit (October 14) and Regional Biotechnology Conference (October 15) Company to participate in 2026 Maxim Growth Summit (October 14) and Regional Biotechnology Conference (October 15)
View source ↗ - Newsglobenewswire.com·55d ago·Neutral
Aprea Therapeutics Announces Second Quarter 2026 Financial Results Enrollment in the ongoing Phase 1 dose escalation ACESOT-1051 trial of oral WEE1 inhibitor APR-1051 is accelerating as dose escalation advances
View source ↗
Earnings
Wed, Nov 11(in 5 weeks)
Consensus estimate $-0.08 per share
Typical surprise +15.8% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 12$-0.07 vs $-0.18beat
- Wed, May 13$-0.22 vs $-0.23beat
- Mon, Mar 16$-0.32 vs $-0.38beat
- Wed, Nov 12$-0.47 vs $-0.11miss
- Tue, Aug 12$-0.53 vs $-0.77beat
- Wed, May 14$-0.66 vs $-0.65miss
Estimates and results for APRE via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by APRE officers and directors.
- Bought
- $541k
- Sold
- $30k
37 trades
1 trade
- Hamill John P.bought
- Hamill John P.bought
- Peters Richardbought
- Peters Richardbought
- Gilad Orenbought
- Gilad Orenbought
- Hamill John P.bought
- Hamill John P.bought
62 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in APRE.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.